Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:ADXS NASDAQ:ATHE NASDAQ:IMNN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.30+3.6%$1.18$0.88▼$5.48$33.67M0.5685,210 shs121,967 shsADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AATHEAlterity Therapeutics$4.02$4.09$2.66▼$7.00$35.66M0.316,764 shs10,300 shsIMNNImunon$2.09-2.3%$2.74$2.06▼$27.65$8.81M1.9572,337 shs19,459 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-8.09%-3.10%+21.36%-13.79%-18.83%ADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,712.46%ATHEAlterity Therapeutics-0.64%-1.62%-14.96%+18.06%-12.74%IMNNImunon-0.47%-2.73%-23.57%-38.15%-94.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.30+3.6%$1.18$0.88▼$5.48$33.67M0.5685,210 shs121,967 shsADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/AATHEAlterity Therapeutics$4.02$4.09$2.66▼$7.00$35.66M0.316,764 shs10,300 shsIMNNImunon$2.09-2.3%$2.74$2.06▼$27.65$8.81M1.9572,337 shs19,459 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-8.09%-3.10%+21.36%-13.79%-18.83%ADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+1,712.46%ATHEAlterity Therapeutics-0.64%-1.62%-14.96%+18.06%-12.74%IMNNImunon-0.47%-2.73%-23.57%-38.15%-94.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 1.00SellN/AN/AADXSAyala Pharmaceuticals 0.00N/AN/AN/AATHEAlterity Therapeutics 2.00HoldN/AN/AIMNNImunon 2.00Hold$10.00378.24% UpsideCurrent Analyst Ratings BreakdownLatest IMNN, ADXS, ATHE, and ABVC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026IMNNImunon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ATHEAlterity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$10.004/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K66.02N/AN/A$0.52 per share2.49ADXSAyala Pharmaceuticals$3.24M11.05N/AN/A($2.06) per share-0.29ATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/AIMNNImunonN/AN/AN/AN/A$2.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$7.91M-$0.40N/AN/AN/AN/A-62.46%-39.99%8/18/2026 (Estimated)ADXSAyala Pharmaceuticals-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/AATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/AN/AIMNNImunon-$14.49M-$5.16N/AN/AN/AN/A-341.23%-153.79%8/4/2026 (Estimated)Latest IMNN, ADXS, ATHE, and ABVC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/A5/12/2026Q1 2026IMNNImunon-$1.2150-$0.84+$0.3750-$0.84N/AN/A3/31/2026Q4 2025IMNNImunon-$1.43-$1.29+$0.14-$1.30($0.73) millionN/A3/3/2026Q4 2025ABVCABVC BioPharmaN/A-$0.11N/A-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/AADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.120.12ADXSAyala PharmaceuticalsN/AN/AN/AATHEAlterity TherapeuticsN/A21.97N/AIMNNImunonN/A1.591.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%ADXSAyala Pharmaceuticals7.18%ATHEAlterity Therapeutics2.14%IMNNImunon4.47%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma19.00%ADXSAyala Pharmaceuticals0.63%ATHEAlterity Therapeutics38.80%IMNNImunon2.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3026.00 million21.06 millionNot OptionableADXSAyala Pharmaceuticals2059.31 million42.36 millionNot OptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableIMNNImunon304.20 million4.08 millionNot OptionableIMNN, ADXS, ATHE, and ABVC HeadlinesRecent News About These CompaniesImunon IMNN Q4 2025 Earnings TranscriptJune 1 at 12:41 PM | finance.yahoo.comImunon Announces CFO Transition and Reappointment of Jeffrey ChurchMay 19, 2026 | theglobeandmail.comImunon Earnings Call Balances Breakthroughs and Cash StrainMay 19, 2026 | tipranks.comImunon targets OVATION 3 last patient enrollment in Q1 2029 while outlining preferred-share financing optionsMay 14, 2026 | seekingalpha.comImunon (IMNN) Q1 2026 Earnings TranscriptMay 14, 2026 | finance.yahoo.comImunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Clinical Progress Amidst Funding ...May 14, 2026 | finance.yahoo.comImunon, Inc. (IMNN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comIMUNON Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comImunon Q1 2026 Earnings PreviewMay 11, 2026 | msn.comIMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026May 5, 2026 | globenewswire.comImunon Adopts Change-of-Control Severance Agreements for ExecutivesMay 4, 2026 | tipranks.comImunon (IMNN) Price Target Decreased by 10.70% to 19.58April 29, 2026 | msn.comMaxim Group initiates coverage of Imunon (IMNN) with buy recommendationApril 18, 2026 | msn.comImunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer TreatmentApril 3, 2026 | news.themarketisopen.comNImunon Earnings Call: Strong Data, Tight Cash RunwayApril 3, 2026 | tipranks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Novo Nordisk (NVO)April 3, 2026 | theglobeandmail.comImunon, Inc. (NASDAQ:IMNN) Q4 2025 Earnings Call TranscriptApril 2, 2026 | insidermonkey.comIMNN: Enrollment in Phase 3 OVATION 3 Trial Remains Ahead of ScheduleApril 1, 2026 | finance.yahoo.comImunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ManagementMarch 31, 2026 | finance.yahoo.comImunon targets ~80 OVATION 3 patients in the next 12 months as cash runway extends into H2 2026March 31, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?By Ryan Hasson | May 12, 2026MongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"By Sam Quirke | June 3, 2026IMNN, ADXS, ATHE, and ABVC Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.30 +0.05 (+3.60%) As of 02:46 PM Eastern This is a fair market value price provided by Massive. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Ayala Pharmaceuticals NASDAQ:ADXS$0.60 0.00 (0.00%) As of 06/1/2026Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Alterity Therapeutics NASDAQ:ATHE$4.02 0.00 (0.00%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Imunon NASDAQ:IMNN$2.09 -0.05 (-2.29%) As of 02:43 PM Eastern This is a fair market value price provided by Massive. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
